AstraZeneca opens research center as UK builds science hub – WBOY.com
LONDON (AP) – Prince Charles praised Cambridge as a center for scientific collaboration on Tuesday as pharmaceutical company AstraZeneca opened a billion pound ($ 1.34 billion) research facility, in hopes to build on the development work of one of the first COVID-19 vaccines.
The 19,000 square meter (over 200,000 square foot) complex near the University of Cambridge will house more than 2,200 researchers. He joins a group of companies seeking to make Cambridge a hub for life sciences research, similar to what California’s Silicon Valley is for the tech industry.
“Having studied in Cambridge myself… over 50 years ago now, one of the things I have always found so special about this city is the way it attracts the meeting of minds, sparks conversations interdisciplinary unique and nurtures collaboration and ingenuity, ”Charles said at the official opening.
Cambridge’s Life Sciences Cluster comprises 631 companies that employ nearly 21,000 people and generate an annual turnover of £ 7 billion, according to Cambridge Ahead, which promotes business development in the city.
AstraZeneca worked with the University of Oxford to develop one of the first COVID-19 vaccines approved by regulators in the UK, European Union and other countries. The company and its licensing partners have shipped more than 1.5 billion doses of the vaccine globally after pledging to sell them nonprofit during the pandemic.
AstraZeneca said last week that it planned to start selling the vaccine at a “modest” profit, although it would continue to offer it to developing countries at cost.
AstraZeneca also plans to apply to the US Food and Drug Administration for approval of the vaccine.
Follow all of AP’s stories about the pandemic at https://apnews.com/hub/coronavirus-pandemic.